Ireland-based Perrigo (NYSE: PRGO) more than halved its second-quarter 2015 earnings on increased expenses.
The company posted earnings per share of $0.39 down from $0.98 a year ago. Earnings, adjusted for non-recurring costs, were $2.18 per share, surpassing the average estimate of 12 analysts surveyed by Zacks Investment Research was for earnings of $1.97 per share.
Net income dropped over 60% to $56.4 million against $131.7 million a year ago. Revenue of $1.53 billion in the period also beat 11 analysts surveyed by Zacks, who expected $1.49 billion.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze